Summary
Therapies which target VEGF and mTOR are now available for patients with metastatic renal cell carcinoma, but there is a continued need to develop agents for patients who become refractory to these initial agents. Tandutinib is a relatively selective inhibitor of type III tyrosine kinase receptor kinases with promising activity in some tumors. In this trial, 10 patients with metastatic renal cell carcinoma refractory to previous therapy with sunitinib or sorafenib (median age 61 years, 80% performance status 0, 60% intermediate MSKCC risk classification) received tandutinib 500 mg bid daily with RECIST-defined response as the primary endpoint and progression-free survival (PFS) and overall survival (OS) as secondary endpoints. No patient had more than 2 cycles of therapy and 50% of patients only received 1 cycle with 70% of patients discontinuing for progressive disease and 30% for toxicity. Tandutinib was not well tolerated with dose reduction in 60% of patients due to adverse events. The most common grade 3 toxicity was fatigue (30%). Tandutinib had no clinical activity and due to the excessive toxicity should not be developed further in patients with sunitinib or sorafenib-refractory metastatic renal cell carcinoma.
Similar content being viewed by others
References
Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318
Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111
Escudier BJ, Bellmunt J, Negrier S, et al: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon alpha2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 27:Abstr 5020, 2009
Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590
Rini BI (2009) Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 115:2306–2312
Rini BI, Halabi S, Rosenberg J, et al: Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 27:Abst LBA 5019, 2009
Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281
Hudes GR (2009) Targeting mTOR in renal cell carcinoma. Cancer 115:2313–2320
Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456
Di Lorenzo G, Carteni G, Autorino R et al (2009) Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 27:4469–4474
Rini BI, Wilding G, Hudes G et al (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462–4468
Sablin MP, Negrier S, Ravaud A et al (2009) Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182:29–34, discussion 34
Corbin AS, Griswold IJ, La Rosee P et al (2004) Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104:3754–3757
Pandey A, Volkots DL, Seroogy JM et al (2002) Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem 45:3772–3793
Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463
Author information
Authors and Affiliations
Corresponding author
Additional information
Research support
This study was supported by the Cancer Therapy Evaluation Program and Millennium Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Shepard, D.R., Cooney, M.M., Elson, P. et al. A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. Invest New Drugs 30, 364–367 (2012). https://doi.org/10.1007/s10637-010-9516-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-010-9516-1